Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SKYZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Shingles Vaccine Market Size

The global shingles vaccine market size was valued at USD 5.43 billion in 2025 and is projected to grow from USD 6.12 billion in 2026 to USD 15.90 billion by 2034, registering a CAGR of 12.68% during the forecast period from 2026 to 2034. North America dominated the shingles vaccine market with a market share of 44.2% in 2025.

The increasing risk of contracting shingles, particularly in persons aged 60 and older, and healthcare policy improvements in developed nations are projected to foster the shingles vaccine market growth. Furthermore, the surge in governments from several nations worldwide is taking initiatives to create awareness and organizing numerous public health campaigns to increase vaccine coverage amongst their citizens, thereby creating opportunities for global market expansion.

Shingles, a viral infection caused by the varicella-zoster virus, causes painful skin rashes and can progress to postherpetic neuralgia (PHN), which is severe nerve pain that persists after the rash has healed. The shingles vaccine stimulates the immune system with a weakened version of the chickenpox virus to combat the disease. This vaccination reduces the risk of developing shingles by roughly 50% and long-term nerve damage by about 65%. There are two main shingles vaccines available: Zostavax and Shingrix.

Zostavax is a live attenuated vaccine, and Shingrix is a recombinant vaccine. Shingrix has been particularly effective, leading to its preference over Zostavax in various countries due to its superior vaccine efficacy, as recommended by health authorities such as the CDC, particularly for adults aged 60 and up, to mitigate the impact of this debilitating condition.

Product Insights

The market is further segmented into Shingrix, Zostavax, and SKYZoster. Shingrix dominates the product segment. Shingrix, developed by GlaxoSmithKline plc., has gained popularity for its superior efficacy and safety profile. Its strong performance in preventing shingles and related complications has solidified its market position. Shingrix's market presence has been strengthened by GlaxoSmithKline plc's strategic focus on research and development, as well as investments in manufacturing facilities and order wins. Shingrix's commitment to innovation and quality has resonated well with healthcare providers and consumers, resulting in widespread global adoption. Shingrix's approval by regulatory bodies such as the FDA, as well as its inclusion in immunization programs in various countries, have all helped to establish and grow its market. With an aging population, rising shingles prevalence, and active government support for vaccination programs, Shingrix is well-positioned to maintain its lead in the shingles vaccine market, providing a dependable and effective solution for shingles prevention and improving public health outcomes.

Request Customizationto receive a tailored report.

Vaccine Type Insights

The market can be bifurcated into recombinant vaccines and live attenuated vaccines. Recombinant Vaccine dominates the vaccine type segment. Recombinant shingles vaccines, such as Shingrix, are designed to prevent herpes zoster (shingles). Unlike older vaccines that use a weakened form of the virus, recombinant vaccines use a key viral protein produced through genetic engineering to trigger an immune response. This protein, glycoprotein E, is combined with an adjuvant to enhance the body's immune response. Shingrix, for example, has shown over 90% effectiveness in preventing shingles and postherpetic neuralgia in adults over 50. It requires two doses administered 2 to 6 months apart. Recombinant vaccines are particularly beneficial for older adults and those with weakened immune systems, as they do not contain live virus and thus pose no risk of causing the disease. Their high efficacy and safety profile make them a significant advancement in shingles prevention.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global shingles vaccine market shareholder over the forecast period. The North American region, particularly the United States and Canada, plays a pivotal role in the global shingles vaccine market. This region's dominance can be attributed to several factors, including high awareness levels, robust healthcare infrastructure, and proactive government policies. In the United States, the Centers for Disease Control and Prevention (CDC) strongly recommends the shingles vaccine for adults aged 50 years and older. The introduction of Shingrix by GlaxoSmithKline in 2017, which boasts over 90% efficacy, significantly boosted market growth. The vaccine's approval and subsequent recommendations by the Advisory Committee on Immunization Practices (ACIP) have led to widespread adoption. Additionally, insurance coverage under the Affordable Care Act ensures that many individuals have access to the vaccine, reducing financial barriers and promoting higher vaccination rates.

• Canada mirrors the U.S. in terms of high vaccination rates, supported by public health campaigns and government-funded immunization programs. The National Advisory Committee on Immunization (NACI) in Canada recommends the shingles vaccine for individuals aged 50 and above, which is also covered by provincial health plans in many regions. These policies contribute to higher vaccination uptake and enhanced public health outcomes. Furthermore, the North American market benefits from a strong emphasis on preventive healthcare, with healthcare providers actively promoting shingles vaccination. Public health campaigns and educational programs further drive awareness, emphasizing the importance of vaccination in preventing shingles and its complications, like postherpetic neuralgia. This comprehensive approach ensures a well-informed public and supports the robust market presence of shingles vaccines in the region.

Asia Pacific Shingles Vaccine Market Trends

The Asia-Pacific region is experiencing rapid growth in the shingles vaccine market, driven by rising disposable incomes, improved healthcare policies, and a substantial population at high risk for shingles. This growth is particularly notable in lower- and middle-income countries where unmet medical needs are prevalent. The acceptance and availability of Shingrix across various Asian nations significantly contribute to the market's expansion. Notably, Japan's Ministry of Health, Labour, and Welfare (MHLW) approved Shingrix's regulatory proposal in June 2022 to prevent shingles in at-risk individuals aged 18 and older. Similarly, GSK launched Shingrix in Singapore in January 2022, making the vaccine widely accessible for shingles prevention.

These strategic moves by market participants, including new approvals and product launches, enhance vaccine dissemination across the region. Additionally, the Asia-Pacific region's expanding healthcare infrastructure and increasing public awareness about shingles vaccination further support market growth. The continuous efforts to improve vaccine availability and the region's proactive healthcare initiatives are projected to drive substantial growth in the shingles vaccine market over the forecast period.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Shingles Vaccine Market